The link between vitamin D, chemerin and metabolic profile in overweight and obese children - preliminary results.
C-reactive protein
chemerin
children
glucose
insulin
lipid profile
obesity
vitamin D
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
13
01
2023
accepted:
06
04
2023
medline:
9
5
2023
pubmed:
8
5
2023
entrez:
8
5
2023
Statut:
epublish
Résumé
Vitamin D affects adipogenesis, oxidative stress, inflammation, secretion of adipocytokines, lipid metabolism and thermogenesis. Some researchers postulate that those effects could be exerted by the influence of vitamin D on chemerin levels. We aimed to investigate if there is a link between serum 25-hydroksyvitamin D [25(OH)D], chemerin and metabolic profile in overweight and obese children before and after vitamin D supplementation. The prospective study included 65 overweight and obese children aged 9.08-17.5 years and 26 peers as a control. None of the patients in the study group had received vitamin D within the last twelve months before the study. The study group had lower baseline 25(OH)D (p<0.001) and higher chemerin (p<0.001), triglycerides (TG, p<0.001), triglycerides/high density lipoprotein cholesterol (TG/HDL-C, p<0.001), C-reactive protein (CRP, p<0.05), fasting insulin (p<0.001), Homeostasis Model Assessment - Insulin Resistance (HOMA-IR, p<0.001), alanine aminotransferase (ALT, p<0.001) and uric acid (p<0.001) compared to the control group. Baseline vitamin D was related to fasting insulin (R=-0.29, p=0.021), HOMA-IR (R=-0.30, p=0.016), HDL-C (R=0.29, p=0.020) and uric acid (R=-0.28, p=0.037) in the study group. Baseline chemerin was related to insulin at 30' (R=0.27, p=0.030), 60' (R=0.27, p=0.033), 90' (R=0.26, p=0.037) and 120' (R=0.26, p=0.040) during the oral glucose tolerance test (OGTT) and ALT (R=0.25, p=0.041) in the study group. Correlation between vitamin D and chemerin (R=-0.39, p=0.046) was found only in the control group. After six months of vitamin D supplementation a decrease in CRP (p<0.01), total cholesterol (p<0.05), ALT (p<0.01), glucose at 150' OGTT (p<0.05) was observed. Moreover, we noticed a tendency for negative association between 25(OH)D and chemerin levels (p=0.085). Multivariable backward linear regression models were build using baseline vitamin D, baseline chemerin and six months chemerin as the dependent variables. Our study confirmed that vitamin D has positive effect on metabolic profile in overweight and obese children. The relationship between vitamin D and chemerin is not clear, nevertheless we have observed a tendency to decrease chemerin concentrations after improving vitamin D status, even without a significant reduction in body fat mass.
Sections du résumé
Background
Vitamin D affects adipogenesis, oxidative stress, inflammation, secretion of adipocytokines, lipid metabolism and thermogenesis. Some researchers postulate that those effects could be exerted by the influence of vitamin D on chemerin levels.
Aim of the study
We aimed to investigate if there is a link between serum 25-hydroksyvitamin D [25(OH)D], chemerin and metabolic profile in overweight and obese children before and after vitamin D supplementation.
Material and methods
The prospective study included 65 overweight and obese children aged 9.08-17.5 years and 26 peers as a control. None of the patients in the study group had received vitamin D within the last twelve months before the study.
Results
The study group had lower baseline 25(OH)D (p<0.001) and higher chemerin (p<0.001), triglycerides (TG, p<0.001), triglycerides/high density lipoprotein cholesterol (TG/HDL-C, p<0.001), C-reactive protein (CRP, p<0.05), fasting insulin (p<0.001), Homeostasis Model Assessment - Insulin Resistance (HOMA-IR, p<0.001), alanine aminotransferase (ALT, p<0.001) and uric acid (p<0.001) compared to the control group. Baseline vitamin D was related to fasting insulin (R=-0.29, p=0.021), HOMA-IR (R=-0.30, p=0.016), HDL-C (R=0.29, p=0.020) and uric acid (R=-0.28, p=0.037) in the study group. Baseline chemerin was related to insulin at 30' (R=0.27, p=0.030), 60' (R=0.27, p=0.033), 90' (R=0.26, p=0.037) and 120' (R=0.26, p=0.040) during the oral glucose tolerance test (OGTT) and ALT (R=0.25, p=0.041) in the study group. Correlation between vitamin D and chemerin (R=-0.39, p=0.046) was found only in the control group. After six months of vitamin D supplementation a decrease in CRP (p<0.01), total cholesterol (p<0.05), ALT (p<0.01), glucose at 150' OGTT (p<0.05) was observed. Moreover, we noticed a tendency for negative association between 25(OH)D and chemerin levels (p=0.085). Multivariable backward linear regression models were build using baseline vitamin D, baseline chemerin and six months chemerin as the dependent variables.
Conclusions
Our study confirmed that vitamin D has positive effect on metabolic profile in overweight and obese children. The relationship between vitamin D and chemerin is not clear, nevertheless we have observed a tendency to decrease chemerin concentrations after improving vitamin D status, even without a significant reduction in body fat mass.
Identifiants
pubmed: 37152969
doi: 10.3389/fendo.2023.1143755
pmc: PMC10159269
doi:
Substances chimiques
Insulin
0
Triglycerides
0
Uric Acid
268B43MJ25
Vitamin D
1406-16-2
Vitamins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1143755Informations de copyright
Copyright © 2023 Krajewska, Witkowska-Sędek, Rumińska, Kucharska, Stelmaszczyk-Emmel, Sobol, Majcher and Pyrżak.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Clin Endocrinol Metab. 2022 May 17;107(6):1541-1551
pubmed: 35240684
Am J Clin Exp Immunol. 2014 Feb 27;3(1):1-19
pubmed: 24660117
Obes Rev. 2013 Mar;14(3):245-62
pubmed: 23216632
J Nutr. 2010 May;140(5):987-91
pubmed: 20237070
Clin Chim Acta. 2021 Jun;517:41-47
pubmed: 33631197
Pediatrics. 2006 Jun;117(6):2065-73
pubmed: 16740849
J Clin Invest. 2011 May;121(5):1858-70
pubmed: 21490391
Int J Mol Sci. 2019 Jul 31;20(15):
pubmed: 31370263
Front Immunol. 2018 Nov 30;9:2772
pubmed: 30555465
Eur J Pediatr. 2011 May;170(5):599-609
pubmed: 20972688
Arch Med Sci. 2013 Apr 20;9(2):191-200
pubmed: 23671428
Medicine (Baltimore). 2016 Aug;95(35):e4583
pubmed: 27583869
Int J Vitam Nutr Res. 2014;84(1-2):98-107
pubmed: 25835240
J Bone Miner Res. 2010 Feb;25(2):222-34
pubmed: 19929432
Biomedicines. 2022 Mar 03;10(3):
pubmed: 35327393
J Clin Endocrinol Metab. 2008 Nov;93(11):4200-9
pubmed: 18697860
Pediatrics. 2016 Jul;138(1):
pubmed: 27335379
Horm Res Paediatr. 2014;82(2):107-12
pubmed: 25034315
Int J Mol Sci. 2022 Jan 16;23(2):
pubmed: 35055140
Glob Pediatr Health. 2021 May 27;8:2333794X211018352
pubmed: 34104694
Metabolites. 2019 Jun 30;9(7):
pubmed: 31262034
Endokrynol Pol. 2022;73(1):26-34
pubmed: 35119086
Metabolism. 2015 Jan;64(1):131-45
pubmed: 25497344
J Biol Chem. 2007 Sep 21;282(38):28175-88
pubmed: 17635925
J Pediatr Endocrinol Metab. 2012;25(1-2):83-7
pubmed: 22570955
Clin Med Insights Pediatr. 2019 Jun 05;13:1179556519853780
pubmed: 31217700
Eur J Endocrinol. 2019 Oct;181(4):439-450
pubmed: 31408845
J Pediatr Endocrinol Metab. 2016 Jul 1;29(7):777-81
pubmed: 27089407
Int J Mol Sci. 2020 Sep 11;21(18):
pubmed: 32932777
Adv Med Sci. 2017 Sep;62(2):383-386
pubmed: 28551507
Int J Obes (Lond). 2018 Oct;42(10):1743-1752
pubmed: 30030480
Eur J Clin Nutr. 1990 Jan;44(1):45-60
pubmed: 2354692
Adv Med Sci. 2021 Sep;66(2):270-278
pubmed: 34082283
J Exp Med. 2009 Jan 16;206(1):249-58
pubmed: 19114666
World Health Organ Tech Rep Ser. 1995;854:1-452
pubmed: 8594834
Nutrients. 2021 Jan 20;13(2):
pubmed: 33498461
ARYA Atheroscler. 2015 Feb;11(Suppl 1):102-8
pubmed: 26261457
Pediatrics. 2009 Sep;124(3):e371-9
pubmed: 19661053
Int J Obes (Lond). 2014 Jan;38(1):46-52
pubmed: 23736361
Curr Obes Rep. 2019 Dec;8(4):472-479
pubmed: 31691175
Int J Endocrinol Metab. 2019 Jan 07;17(1):e74255
pubmed: 30881469
J Pediatr (Rio J). 2014 Jan-Feb;90(1):28-34
pubmed: 24140383
Intern Emerg Med. 2013 Feb;8(1):33-40
pubmed: 21437585
Ann Agric Environ Med. 2017 Dec 23;24(4):636-639
pubmed: 29284239
Int J Mol Sci. 2019 Mar 05;20(5):
pubmed: 30841637
Arch Argent Pediatr. 2017 Apr 1;115(2):133-139
pubmed: 28318178
Metabolism. 2012 May;61(5):706-14
pubmed: 22136911
Int J Endocrinol. 2012;2012:173581
pubmed: 22966228
J Clin Endocrinol Metab. 2012 Jan;97(1):279-85
pubmed: 22072738
IUBMB Life. 2014 Mar;66(3):147-155
pubmed: 24638917
Arch Med Res. 2016 Oct;47(7):541-549
pubmed: 28262196
Menopause. 2018 May;25(5):574-578
pubmed: 29206770
Hum Biol. 1988 Oct;60(5):709-23
pubmed: 3224965
Stem Cells. 2013 Oct;31(10):2172-82
pubmed: 23766088
Biomedicines. 2022 Aug 07;10(8):
pubmed: 36009457
Hypertens Pregnancy. 2019 Aug;38(3):149-156
pubmed: 30922121
Front Endocrinol (Lausanne). 2018 May 31;9:246
pubmed: 29904370
Arterioscler Thromb Vasc Biol. 2006 Jan;26(1):182-8
pubmed: 16284192
Horm Mol Biol Clin Investig. 2016 Apr 1;26(1):25-42
pubmed: 26910750
Horm Metab Res. 2020 Oct;52(10):732-741
pubmed: 33049785
Med Sci (Basel). 2022 Sep 05;10(3):
pubmed: 36135834
Front Endocrinol (Lausanne). 2019 Mar 01;10:103
pubmed: 30881343
Front Endocrinol (Lausanne). 2022 Jun 13;13:920340
pubmed: 35769088
J Pediatr Endocrinol Metab. 2018 Jan 26;31(2):127-135
pubmed: 29306931
Ther Adv Endocrinol Metab. 2014 Dec;5(6):166-89
pubmed: 25489472
Int J Food Sci Nutr. 2015 Mar;66(2):132-4
pubmed: 25657099
Eur J Clin Invest. 2010 Mar;40(3):277-80
pubmed: 20105226
J Pediatr (Rio J). 2021 May-Jun;97(3):273-279
pubmed: 33022267
Asian J Sports Med. 2010 Sep;1(3):151-8
pubmed: 22375203
Int J Womens Health. 2022 Feb 02;14:107-118
pubmed: 35140527
Nutr Metab Insights. 2021 May 26;14:11786388211018726
pubmed: 34103940
Nutrients. 2021 Dec 15;13(12):
pubmed: 34960039
Int J Environ Res Public Health. 2020 Oct 18;17(20):
pubmed: 33081030